Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

Core Insights - Praxis Precision Medicines, Inc. is set to present data from four late-stage programs focused on epilepsy and movement disorders at the American Academy of Neurology (AAN) 2025 Annual Meeting from April 5 to 9, 2025 in San Diego, California [1] Company Overview - Praxis is a clinical-stage biopharmaceutical company that translates genetic insights into therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance [11] - The company has developed a diversified, multimodal CNS portfolio, including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates [11] Pipeline and Clinical Programs - The company is advancing its innovative pipeline with four late-stage programs that aim to transform patient care [2] - Key clinical updates will be presented from the vormatrigine ENERGY program, along with newly initiated clinical trials enrolling patients across the U.S., Europe, and Latin America [2] - Praxis will host an In-Booth Speaker Showcase featuring experts in the field, aimed at sharing their mission to revolutionize therapies for CNS disorders [2] Presentation Details - Praxis will present multiple poster presentations at the AAN, including: - P5-011: Focus on Essential Tremor Management and Impact, featuring results from an online survey capturing healthcare provider and patient perspectives [3] - P5-012: Characteristics of Adult Essential Tremor Patients in a Decentralized US Clinical Trial [3] - P9-012: An observational study on epilepsy monitoring to better understand the patient journey [4] - P4-006: Updates from the first-in-human Phase 1 clinical trial evaluating the safety and tolerability of vormatrigine [5] Product Highlights - Relutrigine (PRAX-562) is a first-in-class small molecule targeting developmental and epileptic encephalopathies (DEEs), showing promise in preclinical studies for seizure control [6][7] - Vormatrigine (PRAX-628) is a next-generation small molecule for adult focal onset seizures and generalized epilepsy, demonstrating superior selectivity and potency in preclinical models [8] - Elsunersen (PRAX-222) is an antisense oligonucleotide targeting SCN2A gene expression, showing significant seizure reduction in clinical studies [9] - Ulixacaltamide is a selective small molecule inhibitor of T-type calcium channels, currently in development for essential tremor [10]